Mereo BioPharma Group plc (AIM:MPH)
London · Delayed Price · Currency is GBP · Price in GBX 26.50
-0.50 (-1.85%)
At close: Dec 17, 2020
Mereo BioPharma Group Revenue
In the year 2025, Mereo BioPharma Group had annual revenue of $500.00K USD.
Revenue
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$12.82K
Employees
39
Market Cap
32.98M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 500.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Angling Direct | 103.90M |
| Goldplat | 72.22M |
| Pulsar Group | 64.07M |
| XP Factory | 61.13M |
| Cavendish | 56.55M |
| Synectics | 54.85M |
| GetBusy | 22.05M |
| Celebrus Technologies | 17.87M |
Mereo BioPharma Group News
- 6 days ago - JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and ... - GuruFocus
- 6 days ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 7 days ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 14 days ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 14 days ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 14 days ago - Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges - GuruFocus
- 14 days ago - Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation ... - GuruFocus
- 14 days ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq